OGN Organon & Co.
Legal ·
Teamsters Local 710 leads a consolidated New Jersey class action against Organon and unnamed officers. Two derivative suits are stayed, and a July 6 suit against the board and Sun Pharma entities challenges the merger proxy.
Organon agreed on April 26, 2026 to be bought by Sun Pharma for $14.00 a share in cash, a 103% premium to an April 9 close set before a media report. The company's enterprise value is $11.75 billion, and it carries $8.6 billion of debt.
Organon & Co. is a global healthcare company with a portfolio of over 70 products across women's health and general medicines, including biosimilars. Its women's health products are sold primarily for contraception and fertility, with key brands including Nexplanon, NuvaRing and Follistim AQ. Its biosimilars span oncology and immunology, including Ontruzant, Aybintio, Bildyos, Bilprevda, Brenzys, Renflexis, Hadlima and Tofidence. Its established brands include Emgality and Vtama cream 1%. Organon operates six manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom, and distributes products to patients in more than 140 countries and territories. In 2025 the company recorded revenues of $6.2 billion, with approximately 74% generated outside the United States. In January 2026 it divested the Jada System to Laborie Medical Technologies Corporation for up to $465 million. Nexplanon is a long-acting reversible contraceptive implant, and in January 2026 the FDA approved a five-year duration-of-use indication for it.
| Product or program | What it is | Stage |
|---|---|---|
| Nexplanon (etonogestrel implant) | Long-acting reversible contraceptive implant | FDA approved five-year duration indication, January 2026 |
| Ontruzant (trastuzumab-dttb) | Trastuzumab biosimilar in oncology | launched in more than 20 countries |
| Bildyos (denosumab-nxxp) | Denosumab biosimilar | launched in the United States in 2025 |
| Hadlima (adalimumab-bwwd) | Adalimumab biosimilar in immunology | launched in five countries |
| Emgality (galcanezumab-gnlm) | Established brand in the cardiovascular, respiratory, dermatology and pain portfolio | |
| Vtama (tapinarof) cream 1% | Established brand for dermatology |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $6.22 billion | $6.40 billion |
| Net income (loss) | $187.0 million | $864.0 million |
| Cash from operations | $700.0 million | $939.0 million |
| Cash and equivalents | $574.0 million | $675.0 million |
Our latest story on this, dated Jul 31, 2026: "Organon faces securities class action over dividend statements and a merger proxy suit". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 31, 2026: "Organon faces securities class action over dividend statements and a merger proxy suit". The story links the filing or release it is based on. Read the story.
Organon & Co. trades under the ticker OGN on NYSE.
Organon & Co. is listed on NYSE. Our directory also records these other listings: BMV:OGN; EUROTLX:4OGN; GETTEX:7XP; LSE:0A9W; LSX:A3CPKP.
The SEC Central Index Key (CIK) for Organon & Co. is 1821825. Its filings are on SEC EDGAR.
262,609,433 shares as of 2026-07-24, per the cover page of its 10-Q filed 2026-07-31.
Our directory records Organon & Co. under United States.
Our directory classifies Organon & Co. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Organon & Co. is US68622V1061.
aibio.space lists Organon & Co. among 2,820 public biotech companies and publishes its news here as stories appear.
Organon & Co. is a global healthcare company with a portfolio of over 70 products across women's health and general medicines, including biosimilars. Its women's health products are sold primarily for contraception and fertility, with key brands including Nexplanon, NuvaRing and Follistim AQ.
Nexplanon (etonogestrel implant): Long-acting reversible contraceptive implant Stage: FDA approved five-year duration indication, January 2026.
Ontruzant (trastuzumab-dttb): Trastuzumab biosimilar in oncology Stage: launched in more than 20 countries.
$6.22 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Organon & Co. reported net income of $187.0 million for the fiscal year ended Dec 31, 2025, and generated $700.0 million of cash from operations, per its annual report to the SEC.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,7.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio